Amylin, Takeda Advance Obesity Drug

Xconomy San Diego — 

San Diego-based Amylin Pharmaceuticals (NASDAQ: AMLN), along with its partner Takeda Pharmaceuticals, said late Monday that their experimental combination of metreleptin and pramlintide is being primed for final-stage Phase III clinical development for obesity. The decision was made after Amylin and Takeda reviewed data from a full 52 weeks of follow up from patients, which showed the drug consistently helped patients lose weight. Separately, Amylin said it is halting development of another obesity drug, davalintide, after a mid-stage trial showed it wasn’t as good as the combination therapy.